Asset / Drug

Dapagliflozin

Drug and asset intelligence for Dapagliflozin with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

SGLT2 Inhibitor

ClinicalJune 21, 2026

A study is underway to assess the impact of dapagliflozin on right ventricular-pulmonary artery coupling in heart failure patients post-surgery.

ClinicalJune 11, 2026

A clinical trial is underway to compare the effectiveness of dapagliflozin and metformin in managing weight gain from antipsychotic medications.

CompetitiveJune 6, 2026

Jiangsu Hansoh Pharma has submitted an original application (ANDA216119) for Dapagliflozin, currently under standard review.

No catalysts indexed for this entity yet.

Topline Data

Monitor the trial outcomes, particularly the TAPSE/PASP ratio changes at 7 months.

June 21, 2026 · N/A

Topline Data

Monitor trial results, particularly weight management outcomes and tolerability data, expected at Week 26.

June 11, 2026 · N/A

Topline Data

Monitor the review progress and any subsequent approval outcomes for ANDA216119.

June 6, 2026 · N/A

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.